Altimmune, Inc. - Common Stock (ALT) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ALT on Nasdaq
Shares outstanding
80,702,987
Price per share
$3.61
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
41,476,255
Total reported value
$156,373,200
% of total 13F portfolios
0%
Share change
+3,833,840
Value change
+$14,303,370
Number of holders
157
Price from insider filings
$3.61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Altimmune, Inc. - Common Stock (ALT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.6% -12% $23,736,362 -$100,148 6,133,427 -0.42% BlackRock, Inc. 30 Jun 2025
AMERIPRISE FINANCIAL INC 1.9% -79% $7,306,296 -$19,283,488 1,443,932 -73% Ameriprise Financial, Inc. 31 Mar 2025

As of 30 Sep 2025, 157 institutional investors reported holding 41,476,255 shares of Altimmune, Inc. - Common Stock (ALT). This represents 51% of the company’s total 80,702,987 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Altimmune, Inc. - Common Stock (ALT) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 7.9% 6,373,638 +23% 0% $24,028,615
BlackRock, Inc. 7.9% 6,373,259 +0.01% 0% $24,027,185
STATE STREET CORP 4.5% 3,601,255 +31% 0% $13,576,731
TANG CAPITAL MANAGEMENT LLC 2.6% 2,131,307 -22% 0.31% $8,035,027
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,017,385 +4.3% 0% $7,607,047
TWO SIGMA INVESTMENTS, LP 2.5% 1,996,848 +357% 0.01% $7,528,117
MORGAN STANLEY 1.8% 1,491,049 +78% 0% $5,621,255
TWO SIGMA ADVISERS, LP 1.8% 1,428,400 +1006% 0.01% $5,385,068
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.7% 1,374,182 -15% 0.01% $5,180,666
CITADEL ADVISORS LLC 1.6% 1,282,014 +145% 0% $4,833,193
Knoll Capital Management, LLC 1.4% 1,121,524 0% 2.3% $4,228,145
NORTHERN TRUST CORP 0.81% 657,016 +2.6% 0% $2,476,950
UBS Group AG 0.8% 642,837 -28% 0% $2,423,496
Squarepoint Ops LLC 0.72% 584,696 0% $2,204,304
GOLDMAN SACHS GROUP INC 0.7% 562,257 +13% 0% $2,119,709
Point72 Asset Management, L.P. 0.59% 476,926 0% $1,798,010
FMR LLC 0.55% 445,137 +11% 0% $1,678,167
Beirne Wealth Consulting Services, LLC 0.51% 410,458 +20% 0.37% $1,547,427
MILLENNIUM MANAGEMENT LLC 0.46% 367,582 +369% 0% $1,385,784
D. E. Shaw & Co., Inc. 0.45% 360,395 +603% 0% $1,358,689
Bank of New York Mellon Corp 0.42% 341,985 +3% 0% $1,289,285
BARCLAYS PLC 0.42% 340,283 +17% 0% $1,282,867
BANK OF AMERICA CORP /DE/ 0.4% 320,440 -55% 0% $1,208,059
DIMENSIONAL FUND ADVISORS LP 0.37% 297,789 -33% 0% $1,122,734
JANE STREET GROUP, LLC 0.35% 280,199 0% $1,056,350

Institutional Holders of Altimmune, Inc. - Common Stock (ALT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 229,511 $828,361 +$1,525 $3.61 10
2025 Q3 41,476,255 $156,373,200 +$14,303,370 $3.77 157
2025 Q2 37,594,851 $145,435,659 -$6,199,092 $3.87 179
2025 Q1 38,134,819 $190,969,777 -$15,358,703 $5.00 173
2024 Q4 40,453,394 $291,649,491 +$7,414,850 $7.21 180
2024 Q3 39,490,913 $242,642,286 -$19,754,298 $6.14 167
2024 Q2 42,376,353 $281,796,522 -$21,723,923 $6.65 173
2024 Q1 44,351,359 $451,471,154 +$108,533,821 $10.18 166
2023 Q4 33,518,969 $377,122,817 +$87,837,677 $11.25 142
2023 Q3 30,119,653 $78,312,976 -$14,266,982 $2.60 110
2023 Q2 35,266,907 $124,503,782 -$30,995,734 $3.53 118
2023 Q1 40,146,839 $169,418,214 -$115,027,226 $4.22 129
2022 Q4 46,782,400 $769,520,216 +$29,466,534 $16.45 122
2022 Q3 46,027,433 $587,716,469 +$80,574,668 $12.77 116
2022 Q2 39,903,915 $466,872,641 +$78,793,572 $11.70 102
2022 Q1 33,651,643 $207,371,526 +$5,868,022 $6.09 96
2021 Q4 32,470,413 $295,787,573 -$27,220,088 $9.16 98
2021 Q3 32,076,209 $363,055,937 +$59,058,531 $11.31 113
2021 Q2 27,191,172 $267,846,675 +$16,710,421 $9.85 102
2021 Q1 23,819,490 $336,535,131 +$49,552,065 $14.13 92
2020 Q4 20,471,521 $230,916,860 -$28,712,052 $11.28 83
2020 Q3 21,898,188 $289,049,000 +$115,723,197 $13.20 67
2020 Q2 13,311,955 $142,567,171 +$125,471,540 $10.71 53
2020 Q1 1,583,373 $5,082,210 +$1,206,160 $3.21 20
2019 Q4 1,281,842 $2,423,890 +$314,812 $1.89 21
2019 Q3 1,113,862 $2,171,952 +$159,903 $1.95 22
2019 Q2 1,032,457 $2,456,382 -$456,118 $2.37 15
2019 Q1 1,114,198 $3,229,903 +$1,231,709 $2.90 13
2018 Q4 806,802 $1,663,208 +$928,520 $2.06 16
2018 Q3 193,862 $853,444 +$853,440 $4.40 7